PF-03758309

PF-03758309 is a potent, orally available small molecule inhibitor of p21-activated kinase 4 (PAK4), a serine/threonine kinase implicated in cancer cell motility, proliferation, and survival. It acts as an ATP-competitive inhibitor with high affinity for PAK4 (Kd = 2.7 nM; Ki = 18.7 nM) and also inhibits other group II PAK isoforms[1][3][6]. In preclinical studies, PF-03758309 demonstrated antiproliferative effects and induced apoptosis in various tumor models by inhibiting phosphorylation of the PAK4 substrate GEF-H1 and blocking anchorage-independent growth of tumor cell lines[3][6]. The drug was developed primarily for the treatment of advanced solid tumors such as colorectal cancer, non-small cell lung cancer (NSCLC), and pancreatic cancer[5][7]. Despite promising preclinical activity and tolerability in early clinical trials, it failed to show clinical benefit in human studies[8].